Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy

Paolo Foa, Mauro Pomati, Sonia Ribera, Sarah Caldiera, Francesco Bertoni, Monica Fornier, Anna Teresa Maiolo

Research output: Contribution to journalArticle

Abstract

Fluorescence in situ hybridization (FISH) is a quantitative technique which allows, by means of specific probes, to detect the t(9;22) translocation typical of chronic myeloid leukemia (CML) hematopoietic cells. We have evaluated FISH on interphase nuclei as a method for assessment of residual disease in bone marrow samples from 5 Philadelphia chromosome positive (Ph+) CML patients after 12 months therapy with interferon alpha; results were compared with findings obtained by conventional cytogenetics and by polymerase chain reaction (PCR). Our data indicate that FISH is more sensitive than cytogenetics for evaluation of residual disease, being positive in 1 out of 2 cases scored as Ph negative by cytogenetics, but is less sensitive than PCR which turned out to be positive in all patients. As additional advantage over conventional cytogenetics, FISH on interphase nuclei can be performed also on samples lacking metaphases or having poor chromosome spreading or unsatisfactory chromosome banding.

Original languageEnglish
Pages (from-to)847-849
Number of pages3
JournalOncology Reports
Volume3
Issue number5
Publication statusPublished - Sep 1996

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fluorescence In Situ Hybridization
Interferon-alpha
Cytogenetics
Interphase
Bone Marrow Diseases
Chromosome Banding
Polymerase Chain Reaction
Therapeutics
Metaphase
Chromosomes

Keywords

  • chronic myeloid leukemia
  • fluorescence in situ hybridization
  • interferon alpha
  • minimal residual disease

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy. / Foa, Paolo; Pomati, Mauro; Ribera, Sonia; Caldiera, Sarah; Bertoni, Francesco; Fornier, Monica; Maiolo, Anna Teresa.

In: Oncology Reports, Vol. 3, No. 5, 09.1996, p. 847-849.

Research output: Contribution to journalArticle

Foa, Paolo ; Pomati, Mauro ; Ribera, Sonia ; Caldiera, Sarah ; Bertoni, Francesco ; Fornier, Monica ; Maiolo, Anna Teresa. / Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy. In: Oncology Reports. 1996 ; Vol. 3, No. 5. pp. 847-849.
@article{d6977547bbee4bac80151119d18c04d9,
title = "Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy",
abstract = "Fluorescence in situ hybridization (FISH) is a quantitative technique which allows, by means of specific probes, to detect the t(9;22) translocation typical of chronic myeloid leukemia (CML) hematopoietic cells. We have evaluated FISH on interphase nuclei as a method for assessment of residual disease in bone marrow samples from 5 Philadelphia chromosome positive (Ph+) CML patients after 12 months therapy with interferon alpha; results were compared with findings obtained by conventional cytogenetics and by polymerase chain reaction (PCR). Our data indicate that FISH is more sensitive than cytogenetics for evaluation of residual disease, being positive in 1 out of 2 cases scored as Ph negative by cytogenetics, but is less sensitive than PCR which turned out to be positive in all patients. As additional advantage over conventional cytogenetics, FISH on interphase nuclei can be performed also on samples lacking metaphases or having poor chromosome spreading or unsatisfactory chromosome banding.",
keywords = "chronic myeloid leukemia, fluorescence in situ hybridization, interferon alpha, minimal residual disease",
author = "Paolo Foa and Mauro Pomati and Sonia Ribera and Sarah Caldiera and Francesco Bertoni and Monica Fornier and Maiolo, {Anna Teresa}",
year = "1996",
month = "9",
language = "English",
volume = "3",
pages = "847--849",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy

AU - Foa, Paolo

AU - Pomati, Mauro

AU - Ribera, Sonia

AU - Caldiera, Sarah

AU - Bertoni, Francesco

AU - Fornier, Monica

AU - Maiolo, Anna Teresa

PY - 1996/9

Y1 - 1996/9

N2 - Fluorescence in situ hybridization (FISH) is a quantitative technique which allows, by means of specific probes, to detect the t(9;22) translocation typical of chronic myeloid leukemia (CML) hematopoietic cells. We have evaluated FISH on interphase nuclei as a method for assessment of residual disease in bone marrow samples from 5 Philadelphia chromosome positive (Ph+) CML patients after 12 months therapy with interferon alpha; results were compared with findings obtained by conventional cytogenetics and by polymerase chain reaction (PCR). Our data indicate that FISH is more sensitive than cytogenetics for evaluation of residual disease, being positive in 1 out of 2 cases scored as Ph negative by cytogenetics, but is less sensitive than PCR which turned out to be positive in all patients. As additional advantage over conventional cytogenetics, FISH on interphase nuclei can be performed also on samples lacking metaphases or having poor chromosome spreading or unsatisfactory chromosome banding.

AB - Fluorescence in situ hybridization (FISH) is a quantitative technique which allows, by means of specific probes, to detect the t(9;22) translocation typical of chronic myeloid leukemia (CML) hematopoietic cells. We have evaluated FISH on interphase nuclei as a method for assessment of residual disease in bone marrow samples from 5 Philadelphia chromosome positive (Ph+) CML patients after 12 months therapy with interferon alpha; results were compared with findings obtained by conventional cytogenetics and by polymerase chain reaction (PCR). Our data indicate that FISH is more sensitive than cytogenetics for evaluation of residual disease, being positive in 1 out of 2 cases scored as Ph negative by cytogenetics, but is less sensitive than PCR which turned out to be positive in all patients. As additional advantage over conventional cytogenetics, FISH on interphase nuclei can be performed also on samples lacking metaphases or having poor chromosome spreading or unsatisfactory chromosome banding.

KW - chronic myeloid leukemia

KW - fluorescence in situ hybridization

KW - interferon alpha

KW - minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=0029839007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029839007&partnerID=8YFLogxK

M3 - Article

C2 - 21594466

AN - SCOPUS:0029839007

VL - 3

SP - 847

EP - 849

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -